<!DOCTYPE html>
<html lang="en">

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
  <meta name="description" content="">
  <meta name="author" content="">

  <title>muoten.github.io: Data (&amp;) Science (&amp;) ...</title>

  <!-- Bootstrap core CSS -->
  <link href="vendor/bootstrap/css/bootstrap.min.css" rel="stylesheet">

  <!-- Custom fonts for this template -->
  <link href="https://fonts.googleapis.com/css?family=Saira+Extra+Condensed:500,700" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Muli:400,400i,800,800i" rel="stylesheet">
  <link href="vendor/fontawesome-free/css/all.min.css" rel="stylesheet">

  <!-- Custom styles for this template -->
  <link href="css/resume.min.css" rel="stylesheet">
<script>
$(document).ready(function() {
    if(window.location.hash) {
        $('html, body').animate({
            scrollTop: $(window.location.hash).offset().top - 20
        }, 500);
    }
});
</script>
</head>

<body id="page-top">

  <nav class="navbar navbar-expand-lg navbar-dark bg-primary fixed-top" id="sideNav">
    <a class="navbar-brand js-scroll-trigger" href="#page-top">
      <span class="d-block d-lg-none">Data (&amp;) Science (&amp;)...</span>
      <span class="d-none d-lg-block">
        <img class="img-fluid img-profile rounded-circle mx-auto mb-2" src="img/profile.png" alt="Profile picture or avatar">
      </span>
    </a>
    <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarSupportedContent" aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>
    <div class="collapse navbar-collapse" id="navbarSupportedContent">
      <ul class="navbar-nav">
        <li class="nav-item">
          <a class="nav-link js-scroll-trigger" href="#about">About</a>
        </li>
        <li class="nav-item">
          <a class="nav-link js-scroll-trigger" href="#covid19">COVID-19 sections:</a>
        </li>
        <li>
        <ul>
        <li class="nav-item">
          <a class="nav-link js-scroll-trigger" href="#covid19-estimates">Context</a>
        </li>
        <li class="nav-item">
          <a class="nav-link js-scroll-trigger" href="#covid19-ages">Analysis</a>
        </li>
        <li class="nav-item">
          <a class="nav-link js-scroll-trigger" href="#covid19-epcalc">Simulations</a>
        </li>
        <li class="nav-item">
          <a class="nav-link js-scroll-trigger" href="#covid19-data">References</a>
        </li>
      </ul>
      <ul class="navbar-nav">
        <li class="nav-item">
          <a class="nav-link js-scroll-trigger" href="#others">Other topics:</a>
        </li>
        <li>
        <ul>
        <li class="nav-item">
          <a class="nav-link js-scroll-trigger" href="#computervision">Computer Vision</a>
        </li>
        <li class="nav-item">
          <a class="nav-link js-scroll-trigger" href="#hacks">Hackathons/Demos</a>
        </li>
      </ul>
    </li>
    </ul>
  </ul>
  </div>
  </nav>

  <div class="container-fluid p-0">

    <section class="resume-section p-3 p-lg-5 d-flex align-items-center" id="about">
      <div class="w-100">

        <div class="subheading mb-4">Data <small>(&amp;)</small> Science <small>(&amp;)</small> ...

        </div>
        <p class="lead mb-1">personal projects and recommended links, considering that...
        </p>
      <!--  <p>-->
        <ul>
          <li>
          <i>"essentially all models are wrong, but some are useful".</i> <a href="https://rss.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1740-9713.2010.00442.x">Box G.</a> et al.
          </li>
          <li>
          <i>"explicit better than implicit". <a href="https://www.python.org/dev/peps/pep-0020/">The Zen of Python</a> et al.
            (with <a href="https://resources.bibblio.org/hubfs/share/2018-01-24-RecSysLDN-Ravelin.pdf">
              exceptions</a>).
          </i>
          </li>
        </ul>
        <!--</p>-->
        <p class="lead mb-5">I expect models being wrong, but their assumptions explicit.
       </p>
       <p>New <a href="#covid19">COVID-19 sections</a>, with:
       </p>
          <ul>

            <li>
              Context on <!--<a href="#covid19-ref-tweets">articles</a>,-->
              <a href="#covid19-estimates">confirmed cases vs estimates</a><sup><small>(17/05/2020)</small></sup>, <a href="#covid19-estimates-deaths">mortality</a><i><sup><small>(10/04/2020)</small></sup></i>
            </li>
            <li>
            Simulations with <a href="#covid19-epcalc">Epidemic Calculator</a>
            </li>
            <li><i><u>Last updates</u>:
              <a href="#covid19-seroprevalence-bias">seroprevalence bias analysis</a><sup><small>(17/05/2020)</small></sup>,
              <a href="#covid19-data">data sources</a><sup><small>(17/05/2020)</small></sup>
            </i>

              </li>

          </ul>


        <p>Feedback welcome!
        </p>

        <div class="social-icons">
          <a href="https://www.linkedin.com/in/enrique-otero-muras-0aab1a133">
            <i class="fab fa-linkedin-in"></i>
          </a>
          <a href="https://github.com/muoten">
            <i class="fab fa-github"></i>
          </a>
          <a href="https://twitter.com/eoteromuras">
            <i class="fab fa-twitter"></i>
          </a>
        </div>
        <p><br/>
          <i><small>Content layout based on
            <a href="https://github.com/BlackrockDigital/startbootstrap-resume">startbootstrap-resume</a>.
            Custom charts generated with <a href="https://plotly.com/python/plotly-express/">Plotly Express</a>.
          </small>
        </i>
        </p>
      </div>
    </section>





    <section class="resume-section p-3 p-lg-5 d-flex justify-content-center" id="covid19">
      <div class="w-100">
        <h2 class="mb-5">COVID-19</h2>



        <div class="resume-item d-flex flex-column flex-md-row justify-content-between mb-5" id="covid19-estimates">
          <div class="resume-content">
            <h3 class="mb-0">Estimates and Context. Language matters</h3>


          <div class="subheading mb-3" id="covid19-seroprevalence-spain">Preliminary results of Spain's seroprevalence study ENECOVID19
          </div>
          <h6>(Updated 17/05/2020)</h6>
          <p>

          On 13/05/2020, <a href="https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_PRIMERA_RONDA_INFORME_PRELIMINAR.pdf">
            preliminary results</a> of Spain's seroprevalence study ENECOVID were published presenting first estimates of <strong>5% of prevalence</strong>
            of IgG antibodies for SARS-Cov2, estimating a range of uncertainty between 4.7% and 5.4% (IC 95%).
          Considering a population of 47 millions, approximately 2.3 million people would have developed antibodies.
            Same day, COVID-19 confirmed cases on Spain (<i>PCR+</i>) were 229540.
            So the <strong>estimated</strong> number of <strong>infections</strong> occured in Spain could be <strong>10 times higher</strong> than <strong>confirmed cases.</strong>
          </p>
          <p>Anyway report warns these results have to be considered <strong>provisional</strong> as they don't include yet complete information on immunoassays.
          So these estimates have to be read with caution.
        </p>
        <blockquote class="twitter-tweet"><p lang="en" dir="ltr">A new report today from Spain showing intra-country heterogeneity of seroprevalence but overall 5%; very similar to projected in France <a href="https://twitter.com/datadista?ref_src=twsrc%5Etfw">@datadista</a> <a href="https://t.co/VUzsRPFoLu">https://t.co/VUzsRPFoLu</a><br>&quot;Only 2.3 million Spaniards have been infected w/ the coronavirus&quot;<a href="https://t.co/v09Ht86omj">https://t.co/v09Ht86omj</a> via <a href="https://twitter.com/Prodigi0_1?ref_src=twsrc%5Etfw">@Prodigi0_1</a></p>&mdash; Eric Topol (@EricTopol) <a href="https://twitter.com/EricTopol/status/1260666412164542465?ref_src=twsrc%5Etfw">May 13, 2020</a></blockquote> <script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

          <p>
          In summary, for this <i>serosurvey</i> approximately 60000 participants were recruited. Actually 60983 from a list of 81613, as 14549 refused to participate.
          The study observes "remarkable <strong>geographic variability</strong>".
          Concretely, prevalence estimates at province level range from a maximum of 14.2% for the province of Soria to a minimum of 1.1% for the autonomous city of Ceuta, 1.4% for Las Palmas (Canary Islands) and 1.4% the Region of Murcia.
</p>
<p>
          Moreover, Madrid with 11% and other inland and closer provinces from Castilla Leon (the mentioned Soria and also Segovia) and Castilla La Mancha complete the list of regions with higher estimated prevalence.
          Whereas the higher value for coastal provinces is for Barcelona with 7%. Then Malaga with 4%, Bizkaia 3.9% and neighbouring Cantabria 3.2%.
          While all the other coastal 18 provinces are below 3% threshold, including also Canary Islands and Baleares.
        </p>
<br/>
          <p>
          My <i><u>opinion</u></i>  based on the report:
        <i>&lt;personal_bias_alert&gt;</i>
          sample size is large and the information seems very interesting.
          Though results are preliminary and should be considered vith some caution. They will be very useful to provide the basis for better-informed policies and actions.
          As long as they consolidate in the next weeks with the immunoassay data.
          Detail of methodology to be used is explained in Annex 3 of the <a href="https://portalcne.isciii.es/enecovid19/documentos/ene_covid19_dis.pdf">study design</a> (in Spanish).
        </p>
        <p>
          However it's a pity that these preliminary results are presented only in PDF, and they don't include raw data in CSV.
          Transparency but also <strong>data accesibility</strong> should not be considered a luxury. Whereas they don't conflict with other legal or ethical issues.
          Two heads are better than one. But maybe I'm just an idealistic of open source, open science and <strong>reproducible research</strong>.
        <i>&lt;/personal_bias_alert&gt;</i>
      </p>
        <p>
          Anyway... my two cents with some particular open questions, links and <strong>context</strong> regarding the methodology and the results.
        </p>

        <ul>

          <li>
           Questions on methodology:
           <ul>
               <li>could be some unadjusted measure or misclasification bias? More details in <a href="#covid19-seroprevalence-bias">next section</a></li>
               <li>could be some kind of unadjusted selection bias?</li>
           </ul>
         </li>

          <li>
          Questions on geographic variability. Some patterns seems to emerge. Can we estimate the influence of the following interrelated aspects?
          <ul>
            <li>
              population density
            </li>
            <li>proximity/<a href="https://www.medrxiv.org/content/10.1101/2020.05.09.20096339v1">
              communications to big metropolis</a>
            </li>
            <li>
            inland vs coastland, probably related to climate conditions of <a href="https://papers.ssrn.com/sol3/Papers.cfm?abstract_id=3551767">temperature and humidity</a>.
            </li>
            <li>
              cumulative incidence and transmission at the moment of lockdown measures
            </li>
          </ul>
          </li>
        </ul>

<br/>
        <h4 id="covid19-seroprevalence-bias">Test error estimates and (my) simplified bias analysis on ENECOVID preliminary results</h4>
         <h6>(17/05/2020, Work in progress)</h6>
        <p>
          Tests used to detect antibodies, as other kind of clinical measures don't have to be perfect to be useful.
          Generally 2 characteristics define this kind of imperfections: <strong>specificity</strong> (true negative rate) and <strong>sensitivity</strong> (true positive rate or <i>recall</i>).
          Let's say, they relate to the ability to avoid
          <strong>false positives</strong> and <strong>false negatives</strong> respectively.
        </p>
        <p>
          These two kind of errors are also known in statistics as <i>type 1</i> and <i>type 2</i> errors.
          And there is often some unbalance between their corresponding error rates.
          For clinical diagnoses these unbalance can be even desirable, as both type of errors don't have in general the same impact.
        </p>
        <blockquote class="twitter-tweet"><p lang="en" dir="ltr">Iâ€™m not sure who made this, but I might have to stick above my desk because itâ€™s the only way I seem to be able remember the difference between type 1 and type 2 error! <a href="https://t.co/bmk9DI30Jw">pic.twitter.com/bmk9DI30Jw</a></p>&mdash; Dr Ellen GrimÃ¥s (@EllenGrimas) <a href="https://twitter.com/EllenGrimas/status/1171002176551956480?ref_src=twsrc%5Etfw">September 9, 2019</a></blockquote> <script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
        <p>
          But in order to quantify prevalences it's preferable that both errors compensate.
          Or making posterior adjustments if this unbalance is significant and can't be tuned.
        </p>
          When undetected false negatives are not compensated with false positives there is <strong>misclasification bias</strong>, a kind of measure or information bias,
          depending on the taxonomy or scientific literature being consulted.
          Anyhow, independently of terminological considerations it should be adjusted in a similar way as other biases, like selection bias.
          Details of an applied methodology to adjust a particular study similar to ENECOVID can be consulted on
          <a href="https://www.medrxiv.org/content/10.1101/2020.04.14.20062463v1.full.pdf">COVID-19 Antibody Seroprevalence in Santa Clara (California)</a> by E. Bendavid et al (April 11 2020),
          and its <a href="https://www.medrxiv.org/content/medrxiv/suppl/2020/04/17/2020.04.14.20062463.DC1/2020.04.14.20062463-1.pdf">
            statistical appendix</a> (via <a href="https://www.datanalytics.com/2020/04/27/muestreo-sensibilidad-y-especificidad/">@datanalytics</a>).
          <i>Further (and harder) related information can be read on the following scientific reports by
            <a href="https://www.nature.com/articles/srep11861">M.L. Bermingham et al</a> (2015) or
            <a href="http://www.med.mcgill.ca/epidemiology/joseph/publications/Methodological/speybroeck2012.pdf">Speybroeck et al</a> (2012)</i>.

        </p>
        <p>
          The ENECovid19 report with preliminary results briefly describes its methodology to compensate selection bias:
        </p>
        <img src="img/seroprevalence_and_bias_0.png" alt="Seroprevalence methodology. Method to compensate selection bias" style="border:1px solid black">
        <figcaption><small>Source: ENE-COVID19: First Round. <a href="https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_PRIMERA_RONDA_INFORME_PRELIMINAR.pdf">Preliminary results</a></small>
        </figcaption>
        <br/>
        <!--
        <p>
          Though I don't find any details regarding measurement adjustment... and it seems I'm not the only one...
        </p>
        <blockquote class="twitter-tweet"><p lang="es" dir="ltr">Tampoco he visto el el informe INE/ISCIII que se mencione la correcciÃ³n de las estimaciones por la especificidad. MÃ¡s al respecto, (incluyendo cÃ³digo para compensar por una especificidad &lt; 100%) aquÃ­: <a href="https://t.co/Bsvoq6KFtC">https://t.co/Bsvoq6KFtC</a></p>&mdash; Carlos Gil Bellosta (@gilbellosta) <a href="https://twitter.com/gilbellosta/status/1260669385670307846?ref_src=twsrc%5Etfw">May 13, 2020</a></blockquote> <script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
      -->
      <p>Furthermore an adjustment method to compensate possible misclassification bias due to test errors, similar to <a href="https://www.medrxiv.org/content/medrxiv/suppl/2020/04/17/2020.04.14.20062463.DC1/2020.04.14.20062463-1.pdf">Santa Clara's statistical approach</a>, is also detailed
        in Annex 3 of <a href="https://portalcne.isciii.es/enecovid19/documentos/ene_covid19_dis.pdf">ENECOVID study design</a>
      </p>
      <img src="img/seroprevalence_and_bias_4.png" alt="Seroprevalence methodology. Method to compensate misclassification bias" style="border:1px solid black">
      <figcaption><small>Source: ENE-COVID19 <a href="https://portalcne.isciii.es/enecovid19/documentos/ene_covid19_dis.pdf">study design</a></small>
      </figcaption>
      <br/>
        <p>
        However the report with preliminary results warns that results are provisional because of the lack of combination with immunoassay.
        And also mentions in future tense that the combination of rapid tests and immunoassay will correct the minor sensitivity of the former
        with the results of the latter to maximize the representativity and the information quality.
      </p>
        <img src="img/seroprevalence_and_bias_1.png" alt="Seroprevalence methodology to compensate lower sensitivity" style="border:1px solid black">
        <figcaption><small>Source: ENE-COVID19: First Round. <a href="https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_PRIMERA_RONDA_INFORME_PRELIMINAR.pdf">Preliminary report</a></small>
        </figcaption>

        <br/>
        <p>
          So I assume according to this claim that adjustment on sensitivity was not yet applied, and I'll try to infer in a simplified way how we could approximate the
          adjusted seroprevalence according to the current provided numbers.
        </p>
        <p>
        According to the report, rapid tests Orient GeneIgM/IgG were used, from company ZhejiangOrient Gene Biotech. Due to the difficulty of reading IgM band all the results refer to IgG.
        Manufacturer-reported sensitivity and specificity for serological detection of IgG is 97% and 100%. But these values are probably too optimistic.
        Reliability studies performed by ENE-COVID19 documented 79% sensitivity and 100% specificity for IgG.

      </p>
      <img src="img/seroprevalence_and_bias_2.png" alt="Seroprevalence methodology. Estimated specificity and sensitivity of rapid tests" style="border:1px solid black">
      <figcaption><small>Source: ENE-COVID19: First Round. <a href="https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_PRIMERA_RONDA_INFORME_PRELIMINAR.pdf">Preliminary results</a></small>
      </figcaption>
      <br/>
      <p>Annex 1 of study design provides more detail on these reliability studies. So we know 150 PCR samples were used to evaluate the rapid test, being 97 PCR+ and 53 PCR-.
      Under this benchmark global sensitivity for IgG+ was 79.4% and specificity 100%. But due to the small size of evaluated test samples
      we could provide
      more conservative estimations. For specificity our uncertainty margin could be in the interval <math>[98.1% (=53/54), 100%]</math>.
      Whereas for sensitivity we could infer that 77 true positives were detected by IgG,
      <!--so the uncertainty margin would be <math>[78.6% (=77/98), 80.4% (=78/97)]</math>,-->
      and we could estimate also a
      <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661219/figure/F3/">95% confidence interval</a> of <math>[71.4%, 87.4%]</math>.

    </p>
      <img src="img/test_reliability_study.png" alt="Seroprevalence methodology. Reliability study to evaluate specificity and sensitivity of rapid tests" style="border:1px solid black">
      <figcaption><small>Source: ENE-COVID19 <a href="https://portalcne.isciii.es/enecovid19/documentos/ene_covid19_dis.pdf">study design</a></small>
      </figcaption>
      <br/>
      <h6>Assumptions: 100% specificity, lower sensitivity</h6>
      <p>
        With 100% specificity there would be no false positives.
        And with sensitivity of 79%, for a prevalence of 5% there would be 5% of true positives and approximately 1.3% <math>(= 0.21 x 0.05 / 0.79)</math> of false negatives.
        So seroprevalence should rise to 6.3%.
        but slightly higher than preliminary 5% estimate, and also not bounded to the provided 95% confidence interval of 4.7% and 5.4%.
        </p>
        <p>I've detailed the calculation with intermediate steps on false positives and false negatives estimations. But we could use directly the expression from the previous annex:
        </p>
        <p>
        <math>
          Prevalence* = (Prevalence - (1 - Specificity)) / (Sensitivity - (1 - Specificity)) = 0.05 / 0.79 = 6.3%
        </math>

        <p>
          Moreover, the study refers to coherence between immunoassay, considered as "ground truth", and IgG rapid test results,
          being 97.3% for 16953 analysed samples. But... if "ground truth" was 100% reliable, specificity for IgG was 100%
           and prevalence less than 5.4% then sould be 94.6% of true negatives perfectly detected.
           So for the reminder 4.7% to 5.4% the accuracy of IgG rapid test would be approximately
          between 50% <math>(= (0.973 - 0.946) / 0.054)</math> and 42.6% <math>(= (0.973 - 0.953) / 0.047)</math>.
        </p>
        <p>In the worst case, considering the more pessimistic sensitivity for IgG being only 42.6%, or rounding down, <a href="https://www.theguardian.com/books/2011/feb/03/douglas-adams-42-hitchhiker?INTCMP=SRCH">42</a>%,
          which is unlikely, false negatives could approximate to 6.9% <!--(= 0.58 x 0.05 / 0.42),-->
          and estimated seroprevalence would rise to near 12%.
        </p>
        <p>Furthermore, from 247 participants with PCR+, IgG antibodies were detected on 83% <math>(76.2 - 88.2 IC 95%)</math>, as presented in the next table.
        </p>
        <img src="img/seroprevalence_and_bias_3.png" alt="Seroprevalence methodology. IgG detection vs PCR" style="border:1px solid black">
        <figcaption><small>Source: ENE-COVID19: First Round. <a href="https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_PRIMERA_RONDA_INFORME_PRELIMINAR.pdf">Preliminary report</a></small>
        </figcaption>
        <br/>
      <p>
          Assuming 100% reliability on PCR+ and 100% specificity of rapid test, IgG sensitivity could be on the interval between 76.2% and 88.2%.
          For the higher bound, 88.2%, false negatives could approximate to 0.7%
          <!--(=0.118 x 0.05 / 0.882)-->
          and seroprevalence would be around 5.7%.
        </p>

        <p>
          Considering even the most optimistic scenario with 100% specificity and 97% sensitivity reported by the manufacturer,
          false negatives could approximate to 0.1% <!--(=0.03 x 0.05 / 0.97)-->.
          And 5.1% seroprevalence would be in the current provided 95% Interval of Confidence <math>(4.7%, 5.4%)</math>.
          However, with analogous calculation, if sensitivity was lower than 92%,
          seroprevalence would rise above the current provided 5.4% upper bound.
        </p>
        <h6>Assumptions: 99% specificity, 79% sensitivity</h6>
        <p>All the previous calculations based on the assumption that specificity for IgG detection was truly 100%
          as manufacturer claims and reliability studies made for ENE-COVID seemingly registered. But what if this specificity was 99%, for instance?
        </p>
        <p>
          In this case, maintaining the assumption of 79% sensitivity, true positives would have been 4.1%
          with the remainder 0.9% bein false positives, and approximately 1.1% false negatives.
          So actual prevalence would be around 5.2%, between the margins of the provided 95% IC.
          Curiously, as previously said, a worse specificity, undesirable for clinical purposes, would produce
          better raw estimates of prevalence. As long as for each 20 false negatives due to low sensitivity
          we would get 1 false positive due to imperfect specificity.
          And boths effects would compensate each other for an expected prevalence near to 5%.
        </p>
        <!--<img src="https://media.giphy.com/media/SV0kYmJBeXm6Fndmxn/giphy.gif" alt="Rick &nbsp; What's the point giphy" style="width:50%">-->


        <h6>Conclusions</h6>
        <p>While we wait for the immunoassays to be completed to "fine tune" the preliminary ENECOVID seroprevalence estimate,
          we could get some rules of thumb (or <i>cuentas de la vieja</i>) for the effects
          of expected test errors on the 5% provided average value.
          In particular, due to the relation between actual specificity and sensitivity for IgG detection
          with the rapid test Orient Gene Biotech.
        </p>
        <p>
          <u>If sensitivity and specificity for IgG were 100% and 97% as reported by the manufacturer, there would be no significant misclasification bias</u>.
        </p>
        <p>
          Otherwise, if these values approximate to those reported by reliability studies to ENECOVID, we could expect bias.
          Concretely, if sensitivity was 79%, false negative would rise the actual seroprevalence above the provided confidence interval margins.
          Unless this effect was compensated with posterior adjustment or specificity being closer to 99% instead of 100%.
        </p>
        <p>
           And particularly, <u>if specificity of rapid test was indeed 100% and sensitivity for IgG 79%, my (educated?) guess would be
             actual seroprevalence closer to 6.3%</u>. Additionally, a more conservative range of sensitivity estimates between (very pesimistic) 42% and (very optimistic) 97%,
             would broaden the interval of possible seroprevalence between 5.1% and 12%.
        </p>
        <p>The following chart is intended to represent adjusted seroprevalence estimates depending on the relation of specificity and sensitivity,
          for a baseline raw estimate of 5%
        </p>
        <img src="img/sensitivity_specificity_adjustment.png" alt="Sensitivity vs Specificity adjustment" style="width: 80%;">
        <!--<figcaption><small>Adjusted seroprevalence estimates for different values of sensitivity and specificity.</small>
        </figcaption>
      -->
      <br/>

      <p>
      As a limitation of the previous analysis, all the calculations presented here have been applied assuming
      that specificity and sensitivity remain independent of sex, age or presence of symptoms.
      As it's not clear if this assumption is going to be fulfilled, <a href="https://portalcne.isciii.es/enecovid19/documentos/ene_covid19_dis.pdf">ENECOVID study design</a> refers to this issue in its
      Annex 3, describing how a proper adjustment should be done. First of all, the procedure should estimate both sensitivity and specificity
      at subgroups. Subsequently, the prevalence adjustment should be applied at subgroup level before results are promediated.
    </p>

        <p>In any case, despite this possible unadjusted bias, according to the previous (quick & dirty) calculations, actual average seroprevalence in Spain would be still far from remote possibility of "herd immunity",
          though it could affect to Infection Fatality Rate estimates, for instance. And as it was mentioned in the referred preliminary ENECOVID report,
          and also remarked here just a few paragraphs before,
          <u>this sensitivity/specificity bias is expected to be corrected in the next round of results by the combination of estimates from immunoassay</u>.
        </p>
        <p>
        <i>Anyway, my provisionally inferred simplified numbers could be significantly wrong or I could be missing the point.
          In this case, or for any other comment, please, <a href="https://twitter.com/eoteromuras">feedback/criticism is welcome :)</a></i>
        </p>

            <br/>
            <br/>

            <div class="subheading mb-3">Confirmed cases vs. estimates of actual infections (Updated 5/04/2020)</div>
            <p> <strong>Confirmed cases</strong> are only a (generally small and biased) subsample of actual infections.

              How small and how biased?
              It depends on the <strong>testing</strong> resources and protocols applied in each country/region.
            </p>

          <p>
            How many people could be actually infected all around?
            Estimations have been done by different models and analysts.
            For instance, the following values have been reported by the
            <a href="https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-04-03-COVID19-Report-14.pdf">
              Imperial College London COVID-19 Response Team
            <img src="img/imperial_college_estimates.png"  alt="Estimates by Imperial College COVID-19 Response Team">
          </a>
        </p>
          <p>
          According to this model, Spain could have around 15% of infected population as of March 28th.
          But the 95% credible interval provided was between 3.7% and 41%. So the <strong>uncertainty</strong> is still huge!
          However, even the lower bound of the estimation corresponded to almost 2 million people.
          Almost 30 times higher than the number of confirmed cases in Spain at that date (72K).
        </p>
        <p><a href="https://twitter.com/kikollan">Kiko Llaneras</a> et al also published at
          <a href="https://elpais.com/sociedad/2020/03/17/actualidad/1584436648_230452.html">elpais.com
          </a>
          4 different calculations, from different researchers and models, ranging from 150K to 900K expected infections
          in Spain at March 24th. When confirmed cases were below 40K according to Spanish government.
        </p>
            <blockquote class="twitter-tweet">
              <p lang="es" dir="ltr">ðŸ”ŽÂ¿CuÃ¡ntos infectados hay realmente en EspaÃ±a?
              Seguramente cientos de miles. Repaso cuatro cÃ¡lculos sencillos pero orientativos que arrojan cifras
              del orden de 300.000 o 900.000 casos: <a href="https://t.co/cACMrd9MHY">https://t.co/cACMrd9MHY</a>
            </p>&mdash; Kiko Llaneras (@kikollan)
            <a href="https://twitter.com/kikollan/status/1242759416446926848?ref_src=twsrc%5Etfw">March 25, 2020</a>
          </blockquote>
          <script async src="https://platform.twitter.com/widgets.js">
          </script>
        <p>

          While the estimations of Imperial College have been broadly communicated in mass media, often ignoring
          the main <strong>assumptions</strong> and confidence intervals underlying the gross numbers,
          I think data team at <i>elpais.com</i>, and specially Llaneras is doing a god job on communicating the numbers
          but also contextualizing assumptions under these numbers.
        </p>
            <p>
              Anyhow, numbers from confirmed cases and notified deaths per country, and alternative
              <strong>estimates</strong> of actual infections and deaths
              infered by different studies and models
              should be understood under their <strong>context</strong>.
              Language should be used rigourously to avoid <i>misinformation</i>.
            </p>




            <p> I personally recommend analysis and data curated by <a href="https://ourworldindata.org/coronavirus">Our World in Data</a>. Thanks to <a href="https://twitter.com/MaxCRoser">Max Roser</a> et al.
                I also appreciate their effort to persuade general press to use adequate terms. And to promote curated analysis from different sources:
            </p>
                <blockquote class="twitter-tweet">
                  <p lang="en" dir="ltr">The study from Timothy Russell and coauthors estimates that only 5.8% of all symptomatic cases in Italy are reported.<a href="https://t.co/d5eRoOltBj">https://t.co/d5eRoOltBj</a>
                    <br><br>Letâ€™s hope Italy is bending the curve.<br><br>But reported cases donâ€™t tell us much when they are likely only a small fraction of the total.
                    <a href="https://t.co/QvvRtzyzVA">pic.twitter.com/QvvRtzyzVA</a></p>&mdash; Max Roser (@MaxCRoser)
                    <a href="https://twitter.com/MaxCRoser/status/1245464450997649411?ref_src=twsrc%5Etfw">April 1, 2020</a>
                  </blockquote>
                  <script async src="https://platform.twitter.com/widgets.js"></script>


            <p> Additional info (Spanish):
            </p>
              <blockquote class="twitter-tweet"><p lang="es" dir="ltr">Como veo que hay mucho lÃ­o con las cifras de casos y muertes por coronavirus, (&quot;vamos mejor o peor que X paÃ­s&quot;, &quot;el gobierno de X paÃ­s miente&quot;, etc.), abro hilo explicativo para intentar que se entiendan mejor los conceptos.
                <a href="https://twitter.com/hashtag/COVID19?src=hash&amp;ref_src=twsrc%5Etfw">#COVID19</a>
                <a href="https://t.co/T2CllkjbUV">pic.twitter.com/T2CllkjbUV</a></p>&mdash; Carlos FernÃ¡ndez (Mejor Prevenir) (@pezcharles)
                <a href="https://twitter.com/pezcharles/status/1244643827060703232?ref_src=twsrc%5Etfw">March 30, 2020</a>
              </blockquote> <script async src="https://platform.twitter.com/widgets.js"></script>

<br/>
<br/>

            <div class="subheading mb-3" id="covid19-estimates-deaths">Reported deaths vs estimates of actual deaths (updated 10-04-2020)</div>
              <!--MoMo: Monitoring of Excess Mortality-->
              <p>
                Moreover the number of confirmed and notified deaths is also an estimation of actual deaths caused by the virus.
                And specially in some countries/regions this value could be highly underestimated.
                Statistics on mortality monitoring on all causes, as project <a href="https://www.euromomo.eu">EuroMomo</a> does,
                can be useful to infer alternative (and better) estimates based on excess mortality.
                This project was launched in 2008 and it uses data from a network of 29 partner Institutes from 26 countries.
                They have accessible maps with weekly estimated deviations from the baseline
                (<a href="https://www.euromomo.eu/outputs/images/z-score_lightbox.fw.png">z-scores</a>)
                 from week 1 of 2010 up until today. And charts with disaggregated <a href="https://www.euromomo.eu/outputs/zscore_country_total.html">
                data by country and age range</a> for the past 4Â½ years.
                <!--In a following section there are some <a href="#covid19-momo-spain">examples extracted from Spanish MoMo Reports 2020</a>
-->
              </p>
                <p>
              <a href="https://www.euromomo.eu">
                <img src="img/euromomo.png"  alt="euromomo.eu map 2020 week 14">
              </a>
              </p>

              <p>Despite the dramatic situation in many places, differences are still huge even for regions in the same country.
                For instance, the following charts belong to the
                <a href="https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/MoMo/Documents/informesMoMo2020/MoMo_Situacion%20a%202%20de%20abril_CNE.pdf">
                  Spanish MoMo report (April 7th):
              <img src="img/momo_spain.png"  alt="euromomo Spain">
              <img src="img/momo_madrid.png"  alt="euromomo Madrid">
                <img src="img/momo_canarias.png"  alt="euromomo Canary Islands">
              </a>
              </p>
              <p>
                We can observe excess mortality has been yet dramatically huge in the second figure representing the Region of Madrid.

                 However the third figure represents Canary Islands, where the first case in Spain was diagnosed.
                 And it shows the impact on mortality in this region has been much lower.
              </p>

              <p>
                Fortunately, after the hard confinement measures decreed by the Spanish Government,
                both regions have current estimations of Basic Reproduction Number (R0) at April 7th near or under 1.
                According to official
                <a href="https://portalcne.isciii.es/covid19/">estimates by the Spanish Ministry of Healthcare</a>,
                R0 estimates would be 0.99 for Madrid and 0.71 for the Canary Islands.
              </p>

              <p>MoMo project in Spain collects information of aproximately 4K civil registers,
                with a coverage of the 92% of the Spanish population. Estimates of expected mortality are based
                on historical averages of observed mortality since January 1th 2008 until one year before the current date.
                This information has been published in reports in PDF format. Buth they have recently developed also an
                <a href="https://momo.isciii.es/public/momo/dashboard/momo_dashboard.html">interactive dashboard</a>
                with access to historical <a href="https://momo.isciii.es/public/momo/dashboard/momo_dashboard.html#datos">
                  data in CSV</a> for the last 2 years.
              </p>
              <p>
                Next figure published by <a href="https://elpais.com/sociedad/2020/04/09/actualidad/1586435286_092135.html">elpais</a>
                presents both the number of deaths registered by MoMo and deaths confirmed with COVID-19 until April 2th in
                the 17 regional autonomies of Spain.
              </p>
              <img src="https://pbs.twimg.com/media/EVOt6YQU8AA2abE?format=jpg&name=medium" alt="Deaths registered by MoMo vs deaths confirmed with COVID-19 in Spain">
<p>
  Despite this chart doesn't show the excess mortality estimates by MoMo, but the total number of deaths, we can
  see that confirmed COVID-19 deaths at april 2th in Madrid or Catalunya are even higher than the total number
  of deaths registered in these regions until April 7th. Whereas in Castilla y LeÃ³n and Castilla La Mancha,
  where high ratios of excess mortality have been detected, the reported COVID-19 deaths have been significantly lower.
</p>
<p>
  <i>Due to the <strong>latency</strong> in collecting this kind of data conclusions have to be read with <strong>caution</strong></i>.
  In some regions latency on notification would be higher than usual due to saturated Civil Registers.
Curiously, the excess mortality estimated by MoMo at April 5th (12940) approximates a lot the 12418 COVID-19
confirmed deaths at country level at the same date.
<!--If this trend consolidates, one possible hypothesis for underestimates and overestimates at region level
could be related with interregional demographics. Maybe many residents in Madrid originary from Castilla y Leon and Castilla La Mancha could have been registered
  as deaths in their regions of birth.-->
</p>

<br/>
<br/>
              <div class="subheading mb-3" id="covid19-momo-spain">Reported case fatality rates vs estimates of actual fatality rates.</div>

              <p>
                It seems that COVID-19 virus (SARS-CoV-2) could be less lethal in relative terms than current figures we get in Italy or Spain
                (<i>estimated deaths/estimated infections</i> would be lower than <i>confirmed deaths/confirmed cases</i>).
                Though much more contagious than we expected. So <i>much more lethal in absolute terms</i>.
                With the aggravating circumstance of saturating healthcare systems
                and increasing even more the number of direct and indirect deaths caused.
              </p>
              <!--<p>
                Both confirmed cases and notified deaths have limitations,
                specially when read on a static basis they don't reveal the actual magnitude of the disease.
                Though, while the protocols don't change for a given series of data,
                they allow to follow trends and monitor the exponential/geometrical growth.
                A critical factor on the expansion of the virus.
              </p>-->
              <p>
              In <a href="https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/20200404_ITCoronavirus.pdf">
                April 4th report by CCAES</a> (Center of Alert Coordination and Healthcare Emergencies),
                a public institution from the Spanish Ministry of Healthcare, says that mortality between overall infected
                population could be between 0.3% and 1%. They refer to an article published on The Lancet by
                <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30567-5/fulltext">Anderson RM et al
                </a>. This is coherent with situation on <a href="https://www.covid.is/data">Iceland</a> where massive testing has been performed.
                Otherwise lethality on hospitalized cases was estimated on 14% at the beginning of the epidemy,
                according to a study by
                <a href="https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.3.2000044">Wu P. et al
                </a> in Wuhan, dated January 23th.
            </p>


            </div>

      </div> <!--   end of <div class="resume-item"> -->



      <div class="resume-item d-flex flex-column flex-md-row justify-content-between mb-5" >
        <div class="resume-content">
          <h3 class="mb-0" id="covid19-ages">Analysis: Confirmed Cases by Age Groups </h3>
          <div class="subheading mb-3">Spain vs Germany (updated 26-04-2020)</div>

          <p>The number of confirmed cases in Germany at April 26th is around 157K people, whereas there are around 226K confirmed cases in Spain
            (<a href="https://www.arcgis.com/apps/opsdashboard/index.html#/85320e2ea5424dfaaa75ae62e5c06e61">Johns Hopkins University</a>,
            <a href="https://www.worldometers.info/coronavirus/#countries">worldometer</a>). But relative lethality estimates by COVID-19 on Germany seems below 4% (<i>confirmed deaths / confirmed cases</i>). Much lower than figures in Spain (10%)
            or Italy (13%).
          </p>
          <p>

            There are several aspects than could explain this big difference.
            But I will focus on the representativity of the sample of confirmed tests in relation to the overall population.
            If we compare the distribution of confirmed cases by age groups in Spain and Germany we can see that:
          </p>
            <ul>
              <li>
            In Spain confirmed cases are biased to ranges of older people. While young people would be underrepresented.
          </li>
          <li>
            In Germany we have just the opposite effect. Though their distribution of confirmed cases is more similar to the overall distribution, people from 60 to 79 would be slightly underrepresented, while age group of 35 to 59 would be overrepresented among confirmed cases.
          </li>
        </ul>


      <p>
        <a href="spain_covid19_by_age.html">
      <img class="covid_by_age" src="img/Spain_covid19_by_age.gif" style="width:350px" alt="Spain: covid-19 confirmed cases by age groups">
    </a>
    <a href="germany_covid19_by_age.html">
      <img class="covid_by_age" src="img/Germany_covid19_by_age.gif" style="width:350px" alt="Germany: covid-19 confirmed cases by age groups">
    </a>
      </p>
          <p>  <a href="https://github.com/muoten/life-expectancy/blob/master/covid-19/covid19_distribution_by_age.ipynb">Code</a>.
          </p>
          <p>
            Thanks to <a href="https://github.com/datadista">datadista</a>,
            <a href="https://npgeo-corona-npgeo-de.hub.arcgis.com/app/478220a4c454480e823b17327b2bf1d4">
            Robert Koch</a> Institute and plotly.
          </p>
          <p>
          Related chart, considering both age and sex groups in Spain:
          </p>
<!--          <p>-->
          <a href="https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20n%C2%BA%2025.%20Situaci%C3%B3n%20de%20COVID-19%20en%20Espa%C3%B1a%20a%2023%20de%20abril%20de%202020.pdf">
<figure>
<img src="img/covid19_by_age_and_sex_spain.png"  alt="COVID-19 by age and sex in Spain"/>
<figcaption><small>Source: Red Nacional de Vigilancia EpidemiolÃ³gica (RENAVE). Instituto de Salud Carlos III (ISCIII)</small>
</figcaption>
</figure>
          </a>
<!--          </p>-->
        <br/>
        <p>
            At the begining of the crisis South Korea was the country with a higher number of tests performed
            and a more representative sample in terms of age distribution. Currently,
            according to Our World in Data, Iceland has performed much more tests per capita.
            Furthermore is a reference on <a href="https://www.covid.is/english">data transparency</a>.
            <iframe src="https://ourworldindata.org/grapher/full-list-cumulative-total-tests-per-thousand?time=latest&country=ECU+EST+ISL+IND+IDN+ITA+NOR+SEN+SGP+ZAF+KOR+CHE+TWN+TUR+GBR+USA+VNM" style="width: 100%; height: 600px; border: 0px none;"></iframe>
        </p>
        <p>
            According to the number of confirmed cases and deaths with COVID-19 on Iceland,
            relative lethality for those tested positive could be below 1%.
            Actually at the time of writing is only around 0.5% in that country.
            Moreover, data from Iceland is helping to get more educated guesses on the proportion of asymptomatic infected people.
            Estimates published on April 14th on <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2006100">Spread of SARS-CoV-2 in the Icelandic Population</a>,
            report that "43% of the participants who tested positive reported having no symptoms, although symptoms almost certainly developed later in some of them.".
            Though these estimations have to be read also with caution as the effect of false positives should be taked into account.
        </p>
        <br/>
          <!--<p>-->
            Additional related information, though less updated:
            <blockquote class="twitter-tweet"><p lang="en" dir="ltr">Here is a distribution of recorded Covid-19 cases in Iceland (which tests broadly, even people with no symptoms) and the Netherlands (which tests narrowly, only those with severe symptoms) <a href="https://t.co/v92fVvOHrT">pic.twitter.com/v92fVvOHrT</a></p>&mdash; Alexandre Afonso (@alexandreafonso) <a href="https://twitter.com/alexandreafonso/status/1243557013759700997?ref_src=twsrc%5Etfw">March 27, 2020</a></blockquote> <script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

        <br/>
            Germany vs South Korea vs Italy, published on March 13th in Medium by
            <a href="https://medium.com/@andreasbackhausab/coronavirus-why-its-so-deadly-in-italy-c4200a15a7bf">
            Andreas Backhaus</a>:
            <a href="https://medium.com/@andreasbackhausab/coronavirus-why-its-so-deadly-in-italy-c4200a15a7bf">
            <figure>
            <img src="https://miro.medium.com/max/1400/1*7UiMwZS1ibeerKx-LfanEA.png"  alt="Coronavirus: why it's so deadly in Italy"/>
          <!--  <figcaption><small>Source: https://medium.com/@andreasbackhausab/coronavirus-why-its-so-deadly-in-italy-c4200a15a7bf</small>
          </figcaption>-->
            </figure>
          </a>

        <!--</p>-->
        </div>
      </div>



        <div class="resume-item d-flex flex-column flex-md-row justify-content-between mb-5" >
          <div class="resume-content">
            <h3 class="mb-0" id="covid19-epcalc">Simulation: Epidemic Calculator</h3>
            <div class="subheading mb-3">SEIR Model applied to Madrid</div>
<p>
              <!--
              <a href="https://gabgoh.github.io/COVID/index.html?p_num_ind=300000&CFR=0.01&D_hospital_lag=5&D_incbation=5.2&D_infectious=2.9&D_recovery_mild=11.1&D_recovery_severe=28.6&I0=1&InterventionAmt=0.33333333333333337&InterventionTime=100&P_SEVERE=0.2&R0=2.2&Time_to_death=32&logN=15.761420707019587">Simulation of COVID-19 evolution on Region of Madrid (Spain)
            </a> -->
            This <a href="https://gabgoh.github.io/COVID/index.html?CFR=0.01&D_hospital_lag=5&D_incbation=5.2&D_infectious=10&D_recovery_mild=11.1&D_recovery_severe=28.6&I0=1&InterventionAmt=0.26&InterventionTime=94.4&P_SEVERE=0.2&R0=3.9&Time_to_death=32&logN=15.761420707019587">simulator</a> implements a classical infectious disease model:
            <i>SEIR (Susceptible â†’ Exposed â†’ Infected â†’ Removed)</i> [<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30260-9/fulltext">Wu, et. al</a>, Kucharski et. al].
            The model uses 13 parameters, including <i>Mortality statistics</i> and the <i>Basic Reproduction Number (R0)</i> before and after the <i>Intervention</i> day.
</p>
<p>
I tried to adjust the evolution of confirmed deaths (<i>Fatalities</i>) in the Region of Madrid since the day this number was over N=10.
Displacing <i>Intervention</i> day relatively to this reference. And ignoring the <i>Day 0</i> as time origin.
<!--I expect that following trends of confirmed fatalities would propagate less uncertainty
and provide more reliable estimates than starting from the first confirmed case.-->
</p>


<!--
<a href="https://gabgoh.github.io/COVID/index.html?p_num_ind=300000&CFR=0.01&D_hospital_lag=5&D_incbation=5.2&D_infectious=2.9&D_recovery_mild=11.1&D_recovery_severe=28.6&I0=1&InterventionAmt=0.33333333333333337&InterventionTime=100&P_SEVERE=0.2&R0=2.2&Time_to_death=32&logN=15.761420707019587">
-->
<a href="https://gabgoh.github.io/COVID/index.html?CFR=0.01&D_hospital_lag=5&D_incbation=5.2&D_infectious=10&D_recovery_mild=11.1&D_recovery_severe=28.6&I0=1&InterventionAmt=0.26&InterventionTime=94.4&P_SEVERE=0.2&R0=3.9&Time_to_death=32&logN=15.761420707019587">
  <img src="img/epcalc_madrid.png"  alt="Epidemic Calculator"/>
</a>
  <p> Concretely, the number of reported deaths on the Region of Madrid at 14th March, when the Spanish Government decreeted
    the state of Alarm, was 213. While only 7 days before, the number was 16. And 3 weeks later this number increased from 213 to
    5136, according to <a href="https://covid19.isciii.es/resources/serie_historica_acumulados.csv">covid19.iscii.es data</a>.
  </p>
  <p>
    I used 1% as <i>Mortality Statistics</i> and 10 days for <i>T<small>inf</small> (Duration patient is infectious)</i>.
    And in order to fit the evolution of confirmed deaths R0 was established to 3.9 before the intervention
    and 1.0 after the intervention.
  </p>
  <p>
    I think the model is useful to have an idea of the interconnected variables and effects.
    <!--And trying to fit the different parameters according to the last knowledge available.-->
    But results from this model should be read with caution.
    Moreover, appart from the uncertainty introduced by many different estimated parameters and hidden variables,
    this implementation of SEIR ignores the effect of the healthcare capacity system,
    and the possibility on mortality increase due to ICU bed shortage.
  </p>
            <p>Thanks to <a href="https://github.com/gabgoh/epcalc">Gabriel Goh epcalc</a> project.
            </p>

          </div>
          <div class="resume-date text-md-right">
            <span class="text-primary">26/4/2020</span>
          </div>
        </div>

        <div class="resume-item d-flex flex-column flex-md-row justify-content-between mb-5" id="covid19-data">
          <div class="resume-content">
            <h3 class="mb-0">COVID-19 Datasets</h3>
            <div class="subheading mb-3">Datasets</div>

              <ul>
                <li><a href="https://github.com/datadista/datasets/tree/master/COVID%2019">Data from Spanish government made accesible on CSV by @datadista</a>
                </li>
                <li><a href="https://momo.isciii.es/public/momo/dashboard/momo_dashboard.html#datos">Mortality by all causes (MoMo), Spain. 2 years of historical data. Daily updates</a>
                </li>
                <li><a href="https://www.covid.is/data">COVID-19 in Iceland â€“ Statistics</a>
                </li>
                <li><a href="https://covidtracking.com/api">The COVID Tracking Project (US)</a>
                </li>
                <li><a href="https://aws.amazon.com/es/data-exchange/covid-19">Data related to COVID-19 available at AWS Data Exchange</a>
                </li>
                <li><a href="https://www.google.com/covid19/mobility/">Google COVID-19 Community Mobility Reports</a>
                </li>
                <li><a href="https://datos.civio.es/dataset/pcr-coronavirus-covid19-espana-comunidades-autonomas/">PCR tests performed by the Autonomous Communities of Spain that communicate these data. By Civio Datos (Spanish)</a>
                </li>
                <li><a href="https://rubenfcasal.github.io/COVID-19/">COVID-19 Data in Spain. By rubenfcasal (Spanish)</a>
                </li>
              </ul>

            <div class="subheading mb-3">Dashboards</div>

            <ul>
              <li><a href="https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6">Coronavirus COVID-19 Global Cases by the CSSE at John Hopkins University</a>
              </li>
              <li><a href="https://www.worldometers.info/coronavirus/#countries">Worldometer. Confirmed Cases and Deaths by Country, Territory or Conveyance</a>
              </li>
              <li><a href="https://experience.arcgis.com/experience/7e30edc490a5441a874f9efe67bd8b89">Official Update of COVID-19 Situation in Singapore</a>
              </li>
              <li><a href="https://datastudio.google.com/u/0/reporting/91350339-2c97-49b5-92b8-965996530f00/page/RdlHB">Date from Italy by Italian Civil Protection Department. Dashboard by @FMossotto</a>
              </li>
            </ul>

            <div class="subheading mb-3">Reports, articles, papers...</div>

            <ul>
              <li><a href="https://ourworldindata.org/coronavirus">Our World in Data. Coronavirus Disease (COVID-19) â€“ Statistics and Research</a>
              </li>
              <li id="euromomo">
                <a href="https://www.euromomo.eu/">EuroMomo: European Monitoring of Excess Mortality for Publich Health Action</a>
              </li>
              <li>
                <a href="https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-04-03-COVID19-Report-14.pdf">
                  Report 14: OnlineCommunity Involvement in COVID-19 Research &amp; Outbreak Response. Pristera P. et al. Imperial College
                </a>
              </li>
              <li>
                <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30260-9/fulltext">
                    Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Wu J.T. et al. The Lancet. Jan 31,2020
                  </a>
              </li>
              <li>
                <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2006100">Spread of SARS-CoV-2 in the Icelandic Population. Gudbjartsson D. et al. The New England Journal of Medicine. April 14th. </a>
              </li>
              <li><a href="https://www.ine.es/covid/covid_movilidad_en.htm">Statistical information for the analysis of the impact of the COVID-19 crisis / Mobility Data. By Spanish INE. With collaboration of the three main mobile operators in Spain (Orange, Telefonica, Vodafone)</a>
              </li>
              <li>
                <a href="https://ncase.me/covid-19/">What Happens Next? COVID-19 Futures, Explained With Playable Simulations (by Marcel SalathÃ© (epidemiologist) & Nicky Case (art/code) 1/05/2020)</a>
                </li>
              <li>
              <a href="https://ourworldindata.org/policy-responses-covid">Policy Responses to the Coronavirus Pandemic (ourworldindata.org 8/05/2020)</a>
            </li>

            </ul>

          <p>
            Seroprevalence analysis, adjustment for selection and misclasification bias:
          </p>
          <ul>
            <li>
              <a href="https://www.medrxiv.org/content/10.1101/2020.04.14.20062463v1.full.pdf">COVID-19 Antibody Seroprevalence in Santa Clara County, California by E. Bendavid et al (April 11 2020)</a>
            </li>
            <li>
              <a href="https://www.medrxiv.org/content/medrxiv/suppl/2020/04/17/2020.04.14.20062463.DC1/2020.04.14.20062463-1.pdf">
                COVID-19 Antibody Seroprevalence in Santa Clara County. Statistical Appendix</a>,
                <a href="https://www.nature.com/articles/srep11861">Hui and Walterâ€™s latent-class model extended to estimate diagnostic test properties from surveillance data: a latent model for latent dataM.L. Bermingham et al, 2015, Nature</a>
            </li>
            <li>
                <a href="http://www.med.mcgill.ca/epidemiology/joseph/publications/Methodological/speybroeck2012.pdf">Misclassification errors in prevalence estimation: Bayesianhandling with care. Speybroeck et al 2012. Int J Public Health</a>
            </li>
          </ul>

          <p>Spanish only:
          </p>
              <ul>
              <li><a href="https://elpais.com/sociedad/2020/04/03/actualidad/1585936102_333545.html">AsÃ­ evoluciona la curva del coronavirus en EspaÃ±a y en cada autonomÃ­a (elpais.com)</a>
              </li>
              <li>
                <a href="https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/MoMo/Documents/informesMoMo2020/MoMo_Situacion%20a%207%20de%20abril_CNE.pdf">Vigilancia de los excesos de mortalidad por todas las causas. MoMo (SituaciÃ³n a 7/4/2020)</a>
              </li>
              <li>
                <a href="https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20n%C2%BA%2025.%20Situaci%C3%B3n%20de%20COVID-19%20en%20Espa%C3%B1a%20a%2023%20de%20abril%20de%202020.pdf">Informe sobre la situaciÃ³n de COVID-19 en EspaÃ±a. 23 abril 2020. RENAVE. CNE. CNM (ISCIII)</a>
              </li>
            <li>
              <a href="https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/20200404_ITCoronavirus.pdf">InformaciÃ³n cientÃ­fica-tÃ©cnica. Enfermedad por coronavirus, COVID-19 (mscbs.gob.es, 4/04/2020)</a>
          </li>
          <li>
            <a href="https://www.elconfidencial.com/tecnologia/ciencia/2020-04-03/covid19-test-pcr-coronavirus-espana_2531844/">Razones (fundamentadas) por las que EspaÃ±a no estÃ¡ haciendo esos 20000 test PCR al dÃ­a (El Confidencial, 3/04/2020)</a>
          </li>
          <li>
            <a href="https://civio.es/medicamentalia/2020/04/08/coronavirus-sars-cov-2-pruebas-pcr-espana/">Sin medios contra el coronavirus: cÃ³mo EspaÃ±a intentÃ³ huir a ciegas del "tsunami" (CIVIO, 8/04/2020)</a>
          </li>
          <li>
            <a href="https://www.eldiario.es/sociedad/muertes-semana-dispara-mortalidad-coronavirus_0_1022248648.html">30.000 muertes que no esperÃ¡bamos: asÃ­ evoluciona la peor crisis de mortalidad desde el inicio de la democracia (eldiario.es 3/05/2020)</a>
          </li>
          <li>
            <a href="https://elpais.com/sociedad/2020/04/25/actualidad/1587831599_926231.html">8.000 muertes sin contabilizar: asÃ­ evoluciona el exceso de fallecidos en EspaÃ±a y cada autonomÃ­a (elpais.com 8/05/2020)</a>
          </li>
          <li>
            <a href="https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_PRIMERA_RONDA_INFORME_PRELIMINAR.pdf">Estudio ENE-COVID19. Primera ronda. Informe preliminar (Spanish Government, 13-05-2020)</a>
          </li>
          <li>
            <a href="https://www.datanalytics.com/2020/04/27/muestreo-sensibilidad-y-especificidad/">Muestreo, sensibilidad y especificidad, por datanalytics</a>
          </li>
         <li>
           <a href="https://portalcne.isciii.es/enecovid19/documentos/ene_covid19_dis.pdf">DiseÃ±o del estudio ENE-COVID19</a>
         </li>
            </ul>



          </div>
          <div class="resume-date text-md-right">
            <span class="text-primary">17/5/2020</span>
          </div>
        </div>


        <!--
        <div class="resume-item d-flex flex-column flex-md-row justify-content-between mb-5">
          <div class="resume-content">
            <h3 class="mb-0">Number of cases and tests per country</h3>
            <div class="subheading mb-3">Demo</div>
            <p>Interactive simple <a href='https://covid-19-data-streamlit.herokuapp.com/'>demo</a>
            </p>
            <p>Thanks to Heroku, streamlit, worldometer...
            </p>
          </div>
          <div class="resume-date text-md-right">
            <span class="text-primary">March 2020</span>
          </div>
        </div>
      -->

      </div>

    </section>

    <hr class="m-0">

    <section class="resume-section p-3 p-lg-5 d-flex justify-content-center" id="others">
      <div class="w-100">
        <h2 class="mb-5">Other topics</h2>

        <div class="resume-item d-flex flex-column flex-md-row justify-content-between mb-5" id="computervision">
          <div class="resume-content">
            <h3 class="mb-0">Car Behavioral Cloning</h3>
            <div class="subheading mb-3">Computer Vision models: Deep Learning vs classical Machine Learning</div>
            <p>Deep Learning: AgÃ¡rrate que vienen curvas / Hold on come curves
            </p>
          <p>
            Custom workshop materials on Deep Learning and classical Machine Learning applied self-driving car simulator. Based on <a href="https://github.com/udacity/CarND-Behavioral-Cloning-P3">Udacity CarND Behavioral Cloning Project</a> and the <a href="https://devblogs.nvidia.com/deep-learning-self-driving-cars/">NVIDIA Convolutional Neural Network model</a>
          </p>
          <p>
            <a href="https://github.com/muoten/car-behavioral-cloning">
            <img src="img/lake_track.png"  alt="Car Behavioral Cloning"/>
            Code
            </a>
          </p>
            <p>Thanks to UDACITY, Nvidia, Keras and <a href="https://github.com/naokishibuya/car-behavioral-cloning">Naoki Shibuya</a> first implementation of car-behavioral-cloning project.
              And also to my colleague <a href="https://github.com/kingkastle">Rafa Castillo</a> and the <a href="https://www.meetup.com/es-ES/meetup-group-ICEMD/events/261039964/">ICEMD</a>.
            </p>

          </div>
          <div class="resume-date text-md-right">
            <span class="text-primary">May 2019</span>
          </div>
        </div>
      </div>

    </section>

    <hr class="m-0">

    <section class="resume-section p-3 p-lg-5 d-flex align-items-center" id="hacks">
      <div class="w-100">
        <h2 class="mb-5">Hackathons &amp; Demos</h2>

        <div class="resume-item d-flex flex-column flex-md-row justify-content-between mb-5">
          <div class="resume-content">
            <h3 class="mb-0">Diversifynd</h3>
            <div class="subheading mb-3">Hackathon StartMeApp Artificial Intelligence 2019</div>
            <p>
              <strong>Diversifynd</strong> is a platform that supports diversity.
            </p>
            <p>Users can check which events or organizations have a better degree of representation in term of gender or race.
              For this purpose computer vision is applied to images of these events or organizations. By traning our custom model.
            </p>
            <p><a href="https://github.com/muoten/diversityscore">
              <img src="img/thealfredolambdas_hackathon.png"  alt="Diversifynd"/>
              Code
            </a>
            </p>
            <p>
              Developed by <i><a href="https://twitter.com/info_hoss/status/1097551695947677696">TheAlfredoLambdas</a></i> (magnificent) team.
              Thanks also to Tensorflow/serving, FaceNet and a project by <a href="https://medium.com/@zhuyan/gender-and-race-recognition-transfer-multi-task-learning-for-the-laziest-88316e6e492"> Zhu Yan</a> And also heroku, azure, docker...
            </p>

          </div>
          <div class="resume-date text-md-right">
            <span class="text-primary">Dic 2018</span>
          </div>
        </div>

        <div class="resume-item d-flex flex-column flex-md-row justify-content-between mb-5">
          <div class="resume-content">
            <h3 class="mb-0">Augmented Choices</h3>
            <div class="subheading mb-3">Hackatrips. Minube and Fitur</div>
            <p><strong>Augmented Choices</strong>: Personalized and Gamified Trip Experiences with Augmented Reality.
            </p>
            <p>
              <a href="https://github.com/muoten/augmented-choices">Code.
              </a>
            </p>
            <p>Developed by <i>TheAlfredoLambdas</i> (splendiferous) team.
              Thanks also to Minube API, Oracle Cloud Platform Container Service, Hotelscombined API...
            </p>
          </div>
          <div class="resume-date text-md-right">
            <span class="text-primary">Jan 2018</span>
          </div>
        </div>

        <div class="resume-item d-flex flex-column flex-md-row justify-content-between mb-5">
          <div class="resume-content">
            <h3 class="mb-0">Berlin &amp; Berlout</h3>
            <div class="subheading mb-3">Techcrunch Disrupt Hackathon Berlin</div>
            <p>Could you get into a berlin exclusive nightclub?
              <strong>Berlout</strong> tells users if they fit the admission criteria for Berlin clubs:
              dark clothes, no jeans, no more than 3 people, around 30s, no laughing, no drinks...

              You only have to take a picture.
              And <i>computer vision</i> algorithm identifies elements related with your probability of being rejected.
              You will see what clubs you could enter with more chances according to this evaluation.
            </p>

            <p>
              <a href="https://github.com/muoten/augmented-choices">
                <img src="img/berlout_screenshot.jpg"  alt="Berlin/Berlout"/>
                Code.
              </a>
            </p>
            <p>Team work. Thanks to <a href="https://twitter.com/chus9000@">Jesus MartÃ­n</a> and the rest of the (marvelous) team! Thanks also to Microsoft Azure Cognitive Services, and Techcrunch, and the <a href="https://techcrunch.com/2017/12/03/unicorn-battle/">unicorns</a>...
            </p>
          </div>
          <div class="resume-date text-md-right">
            <span class="text-primary">Dec 2017</span>
          </div>
        </div>

      </div>


    </section>


  </div>

  <!-- Bootstrap core JavaScript -->
  <script src="vendor/jquery/jquery.min.js"></script>
  <script src="vendor/bootstrap/js/bootstrap.bundle.min.js"></script>

  <!-- Plugin JavaScript -->
  <script src="vendor/jquery-easing/jquery.easing.min.js"></script>

  <!-- Custom scripts for this template -->
  <script src="js/resume.min.js"></script>

</body>
</html>
